FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Saved in:
| Title: | FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. |
|---|---|
| Authors: | Subbiah, V.1 (AUTHOR) VSubbiah@mdanderson.org, Iannotti, N.O.2 (AUTHOR), Gutierrez, M.3 (AUTHOR), Smith, D.C.4 (AUTHOR), Féliz, L.5 (AUTHOR), Lihou, C.F.6 (AUTHOR), Tian, C.6 (AUTHOR), Silverman, I.M.6 (AUTHOR), Ji, T.6 (AUTHOR), Saleh, M.7,8 (AUTHOR) |
| Source: | Annals of Oncology. May2022, Vol. 33 Issue 5, p522-533. 12p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.02.001 |
